Skip to main
LMAT
LMAT logo

LeMaitre Vascular (LMAT) Stock Forecast & Price Target

LeMaitre Vascular (LMAT) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 17%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

LeMaitre Vascular Inc has demonstrated a solid financial performance characterized by an expansion in gross margin by 110 basis points year-over-year to 70%, due to higher average selling prices, manufacturing efficiencies, and an advantageous product mix. The company reported a 15% increase in revenue and a 12% increase in operating income to $16.1 million, translating to an operating margin of 25%, indicating robust operational efficiency and profitability. Additionally, positive momentum is projected for the year, with expectations of a gross margin of 69.7% and an operating income forecasted to reach $60.9 million, reflecting a significant 17% year-over-year increase, further bolstering the positive outlook.

Bears say

LeMaitre Vascular is anticipating a slight decline in its full-year operating margin to 24%, reflecting the impact of seasonality in its business operations. Additionally, the company's target for sales representatives has been reduced from 170 to 165, indicating possible concerns about sales growth and market penetration. Furthermore, the reduction in research and development spending to 6% of revenue raises concerns about the firm's commitment to innovation, which, combined with potential competitive pressures and regulatory challenges, contributes to a negative outlook on the company's future performance.

LeMaitre Vascular (LMAT) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 17% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LeMaitre Vascular and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LeMaitre Vascular (LMAT) Forecast

Analysts have given LeMaitre Vascular (LMAT) a Buy based on their latest research and market trends.

According to 6 analysts, LeMaitre Vascular (LMAT) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $101.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $101.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LeMaitre Vascular (LMAT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.